1. Home
  2. ZLAB vs AMRX Comparison

ZLAB vs AMRX Comparison

Compare ZLAB & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • AMRX
  • Stock Information
  • Founded
  • ZLAB 2013
  • AMRX 2002
  • Country
  • ZLAB China
  • AMRX United States
  • Employees
  • ZLAB N/A
  • AMRX N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • AMRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZLAB Health Care
  • AMRX Health Care
  • Exchange
  • ZLAB Nasdaq
  • AMRX Nasdaq
  • Market Cap
  • ZLAB 3.0B
  • AMRX 2.5B
  • IPO Year
  • ZLAB 2017
  • AMRX N/A
  • Fundamental
  • Price
  • ZLAB $26.91
  • AMRX $7.99
  • Analyst Decision
  • ZLAB Strong Buy
  • AMRX Strong Buy
  • Analyst Count
  • ZLAB 4
  • AMRX 5
  • Target Price
  • ZLAB $52.50
  • AMRX $10.00
  • AVG Volume (30 Days)
  • ZLAB 960.6K
  • AMRX 1.1M
  • Earning Date
  • ZLAB 11-12-2024
  • AMRX 11-08-2024
  • Dividend Yield
  • ZLAB N/A
  • AMRX N/A
  • EPS Growth
  • ZLAB N/A
  • AMRX N/A
  • EPS
  • ZLAB N/A
  • AMRX N/A
  • Revenue
  • ZLAB $355,748,000.00
  • AMRX $2,680,420,000.00
  • Revenue This Year
  • ZLAB $48.50
  • AMRX $17.86
  • Revenue Next Year
  • ZLAB $47.37
  • AMRX $3.90
  • P/E Ratio
  • ZLAB N/A
  • AMRX N/A
  • Revenue Growth
  • ZLAB 35.01
  • AMRX 12.32
  • 52 Week Low
  • ZLAB $13.48
  • AMRX $5.01
  • 52 Week High
  • ZLAB $36.60
  • AMRX $9.48
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 45.71
  • AMRX 42.36
  • Support Level
  • ZLAB $25.85
  • AMRX $7.68
  • Resistance Level
  • ZLAB $29.87
  • AMRX $8.18
  • Average True Range (ATR)
  • ZLAB 1.05
  • AMRX 0.29
  • MACD
  • ZLAB -0.18
  • AMRX -0.04
  • Stochastic Oscillator
  • ZLAB 21.98
  • AMRX 25.41

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.

About AMRX Amneal Pharmaceuticals Inc.

Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Share on Social Networks: